About urogen pharma ltd - URGN
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
URGN At a Glance
UroGen Pharma Ltd.
400 Alexander Park Drive
Princeton, New Jersey 08540
| Phone | 1-646-768-9780 | Revenue | 109.79M | |
| Industry | Biotechnology | Net Income | -153,494,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 21.45% | |
| Fiscal Year-end | 12 / 2026 | Employees | 291 | |
| View SEC Filings |
URGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 10.264 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.27 |
| Enterprise Value to Sales | 10.34 |
| Total Debt to Enterprise Value | 0.115 |
URGN Efficiency
| Revenue/Employee | 377,278.351 |
| Income Per Employee | -527,470.79 |
| Receivables Turnover | 3.319 |
| Total Asset Turnover | 0.452 |
URGN Liquidity
| Current Ratio | 4.008 |
| Quick Ratio | 3.653 |
| Cash Ratio | 2.624 |
URGN Profitability
| Gross Margin | 88.663 |
| Operating Margin | -113.731 |
| Pretax Margin | -139.738 |
| Net Margin | -139.809 |
| Return on Assets | -63.145 |
| Return on Equity | N/A |
| Return on Total Capital | -623.63 |
| Return on Invested Capital | -223.358 |
URGN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 528.53 |
| Total Debt to Total Assets | 64.896 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 521.399 |